Abstract
Recent initiatives by the US Congress and the Food and Drug Administration have provided effective incentives to develop new drugs for children leading to a dramatic increase in the number of paediatric clinical trials being done in the US. There also is increased international interest in development of pharmaceuticals for children as reflected in the draft International Conference on Harmonisation guidelines. The demands created by these initiatives are challenging the industry, regulators, and clinical investigator community. As the infrastructure for paediatric clinical research evolves, it is paramount that the ethical issues unique to children are not forgotten and that children do not become a commodity in the clinical trial economy. Furthermore, it is important to recognise that the adult paradigm for clinical research cannot simply be imposed on paediatric studies and that protocols must be appropriately designed for different age groups. Clinical studies can be, are being, and will continue to be successfully carried out in children on behalf of children so that ultimately children can benefit from therapeutic advances to the same extent enjoyed by their parents and grandparents.
Similar content being viewed by others
References
Food and Drag Administration Modernization Act of 1997, 21 U.S.C. § 301 et seq
21 CFR Parts 201, 312, 314 and 601: Regulations Requiring Manufacturers to Assess the Safety and Effectiveness of New Drags and Biological Products in Pediatric Patients; Final Rule
Clinical Investigation of Medicinal Products in the Pediatric Population. Draft ICH Consensus Guideline, International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, released for consultation at step 2 of the ICH process by the ICH Steering Committee, October 7, 1999
Kauffman RE. Drug safety, testing, and availability for children. Children’s Legal Rights J 1998; 18(2): 27–34
The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research (1978): The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. HEW Publication (OS) 78-0014. Washington, DC
American Academy of Pediatrics Committee on Drugs, Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995; 95: 286–94
Subpart D, Title 45, Code of Federal Regulations, Part 46 (45 CFR 46)
Nelson RM. Children as research subjects. In: Kahn JP, Mastroianni AC, Sugarman J, editors. Beyond consent, seeking justice in research. London: Oxford University Press, 1998: 47–66
Schmidt B, Gillie P, Caco C, et al. Do sick newborn infants benefit from participation in a randomized clinical trial? J Pediatr 1999; 134: 151–5
Reiser J, Warner JO. The value of participating in an asthma trial. Lancet 1985 Jan 26; I: 206–7
Ramsey P. Ethical dimensions of experimental research on children. In: Van Eys J, editor, Research on children: medical imperatives, ethical quandaries, and legal constraints. Baltimore (MD): University Park Press, 1978: 61–4
Acknowledgements
This work supported in part by NICHD Grant # 2-U01 HD31313-07, Children’s Center for Clinical Pharmacology Studies, Paediatric Pharmacology Research Unit Network.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kauffman, R.E. Clinical Trials in Children. Paediatr Drugs 2, 411–418 (2000). https://doi.org/10.2165/00128072-200002060-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128072-200002060-00001